AU5441000A - Human monoclonal antibody - Google Patents

Human monoclonal antibody

Info

Publication number
AU5441000A
AU5441000A AU54410/00A AU5441000A AU5441000A AU 5441000 A AU5441000 A AU 5441000A AU 54410/00 A AU54410/00 A AU 54410/00A AU 5441000 A AU5441000 A AU 5441000A AU 5441000 A AU5441000 A AU 5441000A
Authority
AU
Australia
Prior art keywords
monoclonal antibody
human monoclonal
human
antibody
monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54410/00A
Inventor
Mitchell S. Gross
Raymond W. Sweet
Geraldine Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU5441000A publication Critical patent/AU5441000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU54410/00A 1999-05-18 2000-05-18 Human monoclonal antibody Abandoned AU5441000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13470299P 1999-05-18 1999-05-18
US60134702 1999-05-18
PCT/US2000/013694 WO2000069462A1 (en) 1999-05-18 2000-05-18 Human monoclonal antibody

Publications (1)

Publication Number Publication Date
AU5441000A true AU5441000A (en) 2000-12-05

Family

ID=22464579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54410/00A Abandoned AU5441000A (en) 1999-05-18 2000-05-18 Human monoclonal antibody

Country Status (6)

Country Link
EP (1) EP1178829A4 (en)
JP (1) JP2002543822A (en)
AR (1) AR030019A1 (en)
AU (1) AU5441000A (en)
CO (1) CO5280147A1 (en)
WO (1) WO2000069462A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5057967B2 (en) 2005-03-31 2012-10-24 中外製薬株式会社 sc (Fv) 2 structural isomer
EP1925319B1 (en) * 2005-06-10 2018-03-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
KR101367544B1 (en) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 Stabilizer for protein preparation comprising meglumine and use thereof
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
SI2285408T1 (en) 2008-06-05 2019-02-28 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ES2643034T3 (en) 2009-06-05 2017-11-21 Ablynx N.V. Nanobody constructions against human syncytial respiratory virus (RSVR) trivalent for the prevention and / or treatment of respiratory tract infections
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011064382A1 (en) * 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
TWI659968B (en) * 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2015046467A1 (en) 2013-09-27 2015-04-02 中外製薬株式会社 Method for producing polypeptide heteromultimer
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
BR112018009312A8 (en) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd method for promoting purification efficiency of fc region-containing polypeptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
CA2144043C (en) * 1992-09-16 2005-01-18 Dennis R. Burton Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
EP0977590A4 (en) * 1996-11-01 2001-03-14 Smithkline Beecham Corp Human monoclonal antibodies

Also Published As

Publication number Publication date
JP2002543822A (en) 2002-12-24
EP1178829A1 (en) 2002-02-13
WO2000069462A1 (en) 2000-11-23
CO5280147A1 (en) 2003-05-30
AR030019A1 (en) 2003-08-13
EP1178829A4 (en) 2005-06-08

Similar Documents

Publication Publication Date Title
AU1462300A (en) Human pan-hcv human monoclonal antibodies
AU1290001A (en) Antibodies
AU1704099A (en) Monoclonal human natural antibodies
AU4935000A (en) Antibodies
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2002256895A1 (en) Anti-TRAIL-R antibodies
GB9809839D0 (en) Antibody
AU1550300A (en) Antigen-binding proteins
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU1951201A (en) Peptide antigens
AU5441000A (en) Human monoclonal antibody
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2002365649A1 (en) Anti-dota antibody
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU1598801A (en) HGF-SF monoclonal antibody combinations
AU1608201A (en) Human zven proteins
HUP9800613A3 (en) Humanized antibody against human fas-antigene
AU5970198A (en) Anti-fas antibodies
EP0977590A4 (en) Human monoclonal antibodies
AU2452301A (en) Protein methylarginine-specific antibodies
AU3283500A (en) Tumor-associated antigen
AU1735801A (en) Antibody against human kgfr
AU2002221132A1 (en) Novel antibody
AU5046700A (en) Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
GB9828700D0 (en) Antibody

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase